Key Points
- Insider Ipek Erdogan-Trinkaus sold 3,500 Eton shares at an average price of $67.41, worth about $235,935, reducing their direct stake by 46.17% to 4,081 shares.
- Eton reported quarterly earnings of $0.50 per share, beating the $0.31 consensus estimate, while revenue of $57.93 million exceeded analysts’ $41.98 million forecast.
- Analyst sentiment is generally positive: five analysts rate the stock Buy and one Hold, giving it a “Moderate Buy” consensus and an average price target of $79.75.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider Ipek Erdogan-Trinkaus sold 3,500 shares of the company's stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $67.41, for a total value of $235,935.00. Following the completion of the sale, the insider directly owned 4,081 shares in the company, valued at approximately $275,100.21. The trade was a 46.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eton Pharmaceuticals Price Performance
ETON opened at $61.45 on Friday. The stock has a fifty day simple moving average of $55.18 and a two-hundred day simple moving average of $37.47. The company has a current ratio of 1.79, a quick ratio of 1.58 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 40.70 and a beta of 0.89. Eton Pharmaceuticals, Inc. has a 12-month low of $14.27 and a 12-month high of $70.64.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.31 by $0.19. Eton Pharmaceuticals had a return on equity of 104.82% and a net margin of 35.35%. The business had revenue of $57.93 million during the quarter, compared to analyst estimates of $41.98 million. Research analysts predict that Eton Pharmaceuticals, Inc. will post 1.54 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on ETON. Canaccord Genuity Group increased their price target on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, November 6th. Craig Hallum reissued a "buy" rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. Zacks Research lowered shares of Eton Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. B. Riley Financial upped their price objective on shares of Eton Pharmaceuticals from $70.00 to $81.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Weiss Ratings upgraded shares of Eton Pharmaceuticals from a "hold (c)" rating to a "buy (b-)" rating in a report on Monday. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Eton Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $79.75.
View Our Latest Stock Report on ETON
Institutional Investors Weigh In On Eton Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. Toth Financial Advisory Corp increased its position in shares of Eton Pharmaceuticals by 41.7% during the third quarter. Toth Financial Advisory Corp now owns 1,700 shares of the company's stock valued at $88,000 after acquiring an additional 500 shares in the last quarter. Hilton Head Capital Partners LLC purchased a new position in Eton Pharmaceuticals in the 3rd quarter worth approximately $26,000. Global Retirement Partners LLC purchased a new position in Eton Pharmaceuticals in the 3rd quarter worth approximately $26,000. Morse Asset Management Inc bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at approximately $35,000. Finally, Sterling Capital Management LLC lifted its position in Eton Pharmaceuticals by 845.7% in the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company's stock valued at $46,000 after acquiring an additional 795 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company's stock.
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company's products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
